Eli Lilly $2.25 Billion Notes Offering

Davis Polk advised the joint book-running managers in connection with a $2.25 billion registered offering by Eli Lilly and Company of $750 million principal amount of its 2.350% notes due 2022, $750 million principal amount of its 3.100% notes due 2027 and $750 million principal amount of its 3.950% notes due 2047.

J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Morgan Stanley & Co. LLC acted as representatives of the underwriters.

Headquartered in Indianapolis, Indiana, Eli Lilly discovers, develops, manufactures and markets products in two business segments — human pharmaceutical products and animal health products. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico and 14 other countries. Eli Lilly products are sold in approximately 125 countries.

The Davis Polk corporate team included partners Richard A. Drucker (Picture) and John G. Crowley and associates Ferrell Maguire Keel and Marcus Tan. The tax team included partner Michael Mollerus and associate Kelli A. Rivers. The environmental team included counsel Loyti Cheng. The intellectual property and technology team included counsel David R. Bauer.


Involved fees earner: Richard Drucker – Davis Polk & Wardwell; John G. Crowley – Davis Polk & Wardwell; Ferrell Maguire Keel – Davis Polk & Wardwell; Marcus Tan – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Kelli Rivers – Davis Polk & Wardwell; Loyti Cheng – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Merrill Lynch, Pierce, Fenner & Smith Incorporated; Morgan Stanley; JP Morgan Securities;


Print Friendly, PDF & Email

Author: Ambrogio Visconti